文献速递神经肿瘤小儿神经外科与脑积水

儿童脑桥弥漫性中线胶质瘤立体定向活检的临床结局

Clinical outcomes of stereotactic biopsy on children with pontine diffuse midline glioma.
PubMed 文献 · J Neurooncol · 2023-11-09

回顾性分析25例影像学及临床诊断为脑桥弥漫性中线胶质瘤的患儿,18例(72%)接受活检,7例(28%)拒绝。活检均获得诊断组织,3例(17%)出现术后新发神经功能缺损但均在2周随访时恢复;H3K27M突变者与野生型患者中位总生存期无显著差异,临床试验入组与否的中位总生存期差异亦未达统计学显著。

要点

  • 立体定向活检均获得诊断组织,未出现永久性缺损或并发症。
  • 3例(17%)出现术后新发神经功能缺损,均在2周随访时恢复。
  • H3K27M突变型与野生型患者中位总生存期无显著差异。

核心结论

  • 本系列中,脑桥弥漫性中线胶质瘤立体定向活检未导致永久性缺损或并发症,且所有患者均获得诊断组织。
  • 机器人辅助与非框架立体定向两种活检方式术后病程相似。
  • 生存期基于突变状态或临床试验入组与否均无显著差异。

研究设计与样本

  • 回顾性分析过去5年影像学及临床诊断为脑桥弥漫性中线胶质瘤的患者。
  • 评估人口学、临床、影像学、手术及随访数据。
  • 共纳入25例患者,18例(72%)接受活检,7例(28%)拒绝。

主要发现

  • 12例活检(67%)采用机器人臂,5例(27%)采用无框架立体定向。
  • 3例活检患者(17%)出现术后新发神经功能缺损(1例面瘫、1例VI神经麻痹、1例共济失调),均在2周随访时恢复。
  • 所有活检均获得诊断组织,14例患者(78%)存在H3K27M突变。
  • H3K27M突变患者中位总生存期为10个月,野生型患者为11个月(p=0.30,log-rank检验)。
  • 临床试验入组患者中位总生存期为12个月,未入组患者为8个月(p=0.076)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Diffuse midline glioma (DMG) of the pons occurs in pediatric patients and carries a dismal prognosis. Biopsy is not necessary for diagnosis but provides information, particularly H3K27M status, with prognostic implications. Additionally, biopsy information may open therapeutic options such as clinical trials that require mutation status. Therefore, we sought to assess the safety of surgical biopsy in DMG patients as well as its potential impact on clinical course. METHODS: Retrospective analysis of patients who were radiographically and clinically diagnosed with pontine DMG in the last 5 years was performed. We assessed demographic, clinical, radiographic, surgical, and follow-up data. RESULTS: 25 patients were included; 18 (72%) underwent biopsy while 7 (28%) declined. 12 biopsies (67%) were performed with robotic arm and 5 (27%) with frameless stereotaxy. Three biopsied patients (17%) experienced new post-operative neurologic deficits (1 facial palsy, 1 VI nerve palsy and 1 ataxia) that all resolved at 2-week follow-up. All biopsies yielded diagnostic tissue. Fourteen patients (78%) had H3K27M mutation. Median OS for H3K27M patients was 10 months compared to 11 months in the wild-type patients (p = 0.30, log-rank test). Median OS for patients enrolled in clinical trials was 12 months compared to 8 months for non-trial patients (p = 0.076). CONCLUSION: In our series, stereotactic pontine DMG biopsies did not carry any permanent deficit or complication and yielded diagnostic tissue in all patients. Similar post-operative course was observed in both robot-assisted and frameless stereotactic approaches. There was no significant difference in survival based on mutation status or clinical trial enrollment.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Khan AB, Dang HQ, Gopakumar S, et al. Clinical outcomes of stereotactic biopsy on children with pontine diffuse midline glioma. J Neurooncol. 2023. PMID: 37945818. doi:10.1007/s11060-023-04475-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。